Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Unraveling Prostate Cancer Genomics, Pathology, and Magnetic Resonance Imaging Visibility.

Shoag JE, Tosoian JJ, Salami SS, Barbieri CE.

Eur Urol. 2019 Jan 31. pii: S0302-2838(19)30070-3. doi: 10.1016/j.eururo.2019.01.027. [Epub ahead of print] No abstract available.

PMID:
30712974
2.

Image quality and cancer visibility of T2-weighted magnetic resonance imaging of the prostate at 7 Tesla.

Vos EK, Lagemaat MW, Barentsz JO, Fütterer JJ, Zámecnik P, Roozen H, Orzada S, Bitz AK, Maas MC, Scheenen TW.

Eur Radiol. 2014 Aug;24(8):1950-8. doi: 10.1007/s00330-014-3234-6. Epub 2014 May 28.

PMID:
24865699
3.

Visibility of prostate cancer on transrectal ultrasound during fusion with multiparametric magnetic resonance imaging for biopsy.

van de Ven WJ, Sedelaar JP, van der Leest MM, Hulsbergen-van de Kaa CA, Barentsz JO, Fütterer JJ, Huisman HJ.

Clin Imaging. 2016 Jul-Aug;40(4):745-50. doi: 10.1016/j.clinimag.2016.02.005. Epub 2016 Feb 6.

PMID:
27317220
4.

Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer.

Vargas HA, Akin O, Afaq A, Goldman D, Zheng J, Moskowitz CS, Shukla-Dave A, Eastham J, Scardino P, Hricak H.

J Urol. 2012 Nov;188(5):1732-8. doi: 10.1016/j.juro.2012.07.024. Epub 2012 Sep 25.

5.

Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level.

Beksac AT, Cumarasamy S, Falagario U, Xu P, Takhar M, Alshalalfa M, Gupta A, Prasad S, Martini A, Thulasidass H, Rai R, Berger M, Hectors S, Jordan J, Davicioni E, Nair S, Haines K 3rd, Lewis S, Rastinehad A, Yadav K, Jayaratna I, Taouli B, Tewari A.

J Urol. 2018 Dec;200(6):1241-1249. doi: 10.1016/j.juro.2018.06.041. Epub 2018 Jul 3.

PMID:
30563651
6.

Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.

Lee DH, Koo KC, Lee SH, Rha KH, Choi YD, Hong SJ, Chung BH.

Jpn J Clin Oncol. 2013 May;43(5):553-8. doi: 10.1093/jjco/hyt041. Epub 2013 Apr 11.

PMID:
23580758
7.

Diffusion-weighted magnetic resonance imaging detects significant prostate cancer with high probability.

Bains LJ, Studer UE, Froehlich JM, Giannarini G, Triantafyllou M, Fleischmann A, Thoeny HC.

J Urol. 2014 Sep;192(3):737-42. doi: 10.1016/j.juro.2014.03.039. Epub 2014 Mar 15.

PMID:
24641913
8.

Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies.

Ukimura O, Marien A, Palmer S, Villers A, Aron M, de Castro Abreu AL, Leslie S, Shoji S, Matsugasumi T, Gross M, Dasgupta P, Gill IS.

World J Urol. 2015 Nov;33(11):1669-76. doi: 10.1007/s00345-015-1501-z. Epub 2015 Feb 6.

PMID:
25656687
9.

Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology.

Le JD, Stephenson S, Brugger M, Lu DY, Lieu P, Sonn GA, Natarajan S, Dorey FJ, Huang J, Margolis DJ, Reiter RE, Marks LS.

J Urol. 2014 Nov;192(5):1367-73. doi: 10.1016/j.juro.2014.04.094. Epub 2014 May 1.

10.

Diffusion-weighted magnetic resonance imaging in patients with unilateral prostate cancer on extended prostate biopsy: predictive accuracy of laterality and implications for hemi-ablative therapy.

Jeong IG, Kim JK, Cho KS, You D, Song C, Hong JH, Ahn H, Kim CS.

J Urol. 2010 Nov;184(5):1963-9. doi: 10.1016/j.juro.2010.06.136. Epub 2010 Sep 18.

PMID:
20851437
11.

Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy.

Muthigi A, George AK, Sidana A, Kongnyuy M, Simon R, Moreno V, Merino MJ, Choyke PL, Turkbey B, Wood BJ, Pinto PA.

J Urol. 2017 Feb;197(2):327-334. doi: 10.1016/j.juro.2016.08.097. Epub 2016 Aug 28.

12.

Clinically low-risk prostate cancer: evaluation with transrectal doppler ultrasound and functional magnetic resonance imaging.

Novis MI, Baroni RH, Cerri LM, Mattedi RL, Buchpiguel CA.

Clinics (Sao Paulo). 2011;66(1):27-34.

13.

Role of Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy and Transrectal Ultrasound in Evaluation of Prostatic Pathologies with Focus on Prostate Cancer.

Lahoti AM, Dhok AP, Rantnaparkhi CR, Rawat JS, Chandak NU, Tawari HS.

Pol J Radiol. 2017 Dec 15;82:827-836. doi: 10.12659/PJR.903958. eCollection 2017.

14.

High-Resolution Diffusion-weighted Imaging Increases Prostate Cancer Visibility?

Fütterer JJ.

EBioMedicine. 2016 May;7:12. doi: 10.1016/j.ebiom.2016.04.015. Epub 2016 Apr 16. No abstract available.

15.

Multiparametric Magnetic Resonance Imaging Predicts Postoperative Pathology but Misses Aggressive Prostate Cancers as Assessed by Cell Cycle Progression Score.

Renard-Penna R, Cancel-Tassin G, Comperat E, Varinot J, Léon P, Roupret M, Mozer P, Vaessen C, Lucidarme O, Bitker MO, Cussenot O.

J Urol. 2015 Dec;194(6):1617-23. doi: 10.1016/j.juro.2015.06.107. Epub 2015 Aug 10.

PMID:
26272031
16.

Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer.

Rhee H, Thomas P, Shepherd B, Gustafson S, Vela I, Russell PJ, Nelson C, Chung E, Wood G, Malone G, Wood S, Heathcote P.

J Urol. 2016 Oct;196(4):1261-7. doi: 10.1016/j.juro.2016.02.3000. Epub 2016 May 21.

PMID:
27220897
17.

Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience.

Carlani M, Mancino S, Bonanno E, Finazzi Agrò E, Simonetti G.

Radiol Med. 2008 Aug;113(5):670-88. doi: 10.1007/s11547-008-0271-8. Epub 2008 May 20. English, Italian.

PMID:
18493829
18.

What is the optimal b value in diffusion-weighted MR imaging to depict prostate cancer at 3T?

Metens T, Miranda D, Absil J, Matos C.

Eur Radiol. 2012 Mar;22(3):703-9. doi: 10.1007/s00330-011-2298-9. Epub 2011 Oct 5.

PMID:
21971824
19.

Prostate cancer genomics.

Li PE, Nelson PS.

Curr Urol Rep. 2001 Feb;2(1):70-8. Review.

PMID:
12084298
20.

Multi-institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12-core systematic biopsy.

Truong M, Wang B, Gordetsky JB, Nix JW, Frye TP, Messing EM, Thomas JV, Feng C, Rais-Bahrami S.

Cancer. 2018 Jan 15;124(2):278-285. doi: 10.1002/cncr.31051. Epub 2017 Oct 4.

Supplemental Content

Support Center